<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02671162</url>
  </required_header>
  <id_info>
    <org_study_id>IRCT2015080110410N2</org_study_id>
    <nct_id>NCT02671162</nct_id>
  </id_info>
  <brief_title>Evaluating the Effect of Fumaria Parviflora L. in Uremic Pruritus</brief_title>
  <official_title>Evaluation the Effect of Fumaria Parviflora L. on Uremic Pruritus of End-stage Renal Disease Patients: A Randomized Double- Blind Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiraz University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Fumaria Parviflora L. can minimize severity
      of pruritus in patients with end-stage renal disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uremic Pruritus is still a common complication in end-stage renal disease patients. The
      pathogenesis of Uremic Pruritus is unknown, therefore treatments are ineffective. According
      to several studies Uremic Pruritus is not an isolated skin disease. It seems to be a systemic
      inflammatory disease with a deranged balance of T helper cell differentiation. In this study
      investigators considered to evaluate effect of Fumaria Parviflora L. in uremic pruritus by a
      double blind placebo control clinical trial. It is hypothesized that oral Fumaria Parviflora
      L. may minimize uremic pruritus by decreasing serum Interferon gamma (IFN-γ) and
      high-sensitive C reactive protein (hs-CRP).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of Pruritis as measured by a visual analogue scale (VAS)</measure>
    <time_frame>3 months</time_frame>
    <description>A '0' score represented absence of pruritus and a '10' represented the greatest severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Interferon-gamma level</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum IL‐4 level</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum high-sensitive C reactive protein (hs-CRP)</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Wheat</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule/ 2 capsule 3 times per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fumaria</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fumaria capsule (0.5 mg Fumaria parviflora L.) / 2 capsule 3 times per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Wheat</intervention_name>
    <description>3 times a day each time 2 capsules before eating meal for 8 weeks.</description>
    <arm_group_label>Wheat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fumaria</intervention_name>
    <description>3 times a day each time 2 capsules before eating meal for 8 weeks.</description>
    <arm_group_label>Fumaria</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hemodialysis patients

          -  Suffering from pruritus for at least 6 weeks

          -  Have not responded to other drugs

          -  visual analogue scale (VAS) equal or more than 4

        Exclusion Criteria:

          -  Liver disease

          -  Respiratory disease

          -  Dermatological disease

          -  Hemoglobin less than 10

          -  Cholestasis

          -  Malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamshid Roozbeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pouya Faridi, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rahimeh Akrami, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shiraz University of Medical Sciences</affiliation>
  </overall_official>
  <link>
    <url>https://www.nlm.nih.gov/medlineplus/</url>
    <description>Itching, Kidney Diseases, Kidney Failure</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp</url>
    <description>Fumaria</description>
  </link>
  <reference>
    <citation>Fallahzadeh MK, Roozbeh J, Geramizadeh B, Namazi MR. Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant. 2011 Oct;26(10):3338-44. doi: 10.1093/ndt/gfr053. Epub 2011 Mar 3.</citation>
    <PMID>21372257</PMID>
  </reference>
  <reference>
    <citation>Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, Stülten C, van der Kuip H, Pauli-Magnus C, Raub U, Kuhlmann U, Mettang T. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006 Mar;21(3):749-55. Epub 2005 Oct 25.</citation>
    <PMID>16249205</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2016</study_first_submitted>
  <study_first_submitted_qc>February 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2016</study_first_posted>
  <last_update_submitted>February 1, 2016</last_update_submitted>
  <last_update_submitted_qc>February 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiraz University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Rahimeh Akrami</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>End-Stage Renal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

